This single arm study will evaluate the efficacy and safety of a first-line regimen of Avastin and XELOX (oxaliplatin + Xeloda) in patients with metastatic cancer of the colon or rectum. Patients will
C = cemented; CO = cemented old; CY = cemented young; U = uncemented; UY = uncemented young; H = hybrid; HY = hybrid young; US = unspecified; AR/N = No. at risk at 10 yr/No. of primary operati
